Critical Care Self-Assessment Program (CCSAP) Book 1: Resuscitation and Critical Care Practice (Cert # L249114)

The target audience Critical Care Self-Assessment Program (CCSAP) Book 1: Resuscitation and Critical Care Practice is board-certified and advanced level critical care clinical pharmacists.

Board certified pharmacists are eligible to receive up to 22 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.   

ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.

ACCP and ASHP are approved by BPS as a provider for the recertification of BCCCP.

Resuscitation and Critical Care Practice I
ACPE #: 0217-9999-24-022-H01-P
Chapter: Fluid Resuscitation Volume and Vasopressor Timing in Shock

• Assess clinical markers that guide fluid resuscitation and vasopressor initiation in shock.
• Evaluate patient response to fluid resuscitation and devise a stewardship plan for patient fluid resuscitation.
• Account for the limitations of the Surviving Sepsis Campaign guidelines in relation to vasopressor therapy initiation.
• Develop a plan for the initiation of vasopressor therapy on the basis of patient-specific parameters.
• Justify the role of critical care pharmacists in fluid stewardship and vasopressor initiation in shock. 

Chapter: Selecting Vasopressors in Septic Shock

• Evaluate the mechanisms and consequences of hypotension in septic shock.
• Distinguish the pharmacologic targets and adverse effects of various vasopressors.
• Assess different phenotypes of vasopressor responsiveness.
• Design a plan for applying vasopressors to a patient with septic shock. 

Resuscitation and Critical Care Practice II
ACPE #: 0217-9999-24-023-H01-P
Chapter: Severe Musculoskeletal and Spinal Injuries

• Evaluate patients for potential etiologies of musculoskeletal injuries and corresponding principles of management.
• Apply principles demonstrating the pharmacist’s role in the prevention and treatment of medication-associated musculoskeletal injury.
• Develop a treatment plan for the acute management of musculoskeletal injuries during the pre-hospital, ED, postoperative, and ICU phases of care.
• Design appropriate treatment modalities for patients with spinal cord injury, compartment syndrome, and rhabdomyolysis.
• Design supportive care of a critically ill patient with musculoskeletal injuries including infection prevention and treatment, pain control, and venous thromboembolism prophylaxis. 

Chapter: Immunomodulation in Critical Illness

• Evaluate the role of the immune system in critical illness and approach to immunologic monitoring in the ICU.
• Apply the key physiologic alterations underlying the dysregulated immune response in critical illness and its associated consequences.
• Account for the impact of commonly used therapies in the ICU on the immune system.
• Evaluate the evidence surrounding the use of immunomodulatory agents in critical illness.
• Analyze the current literature evaluating alternative therapies for immune modulation in the ICU. 

Resuscitation and Critical Care Practice III
ACPE #: 0217-9999-24-024-H01-P
Chapter: Developing and Advancing Critical Care Pharmacy Practice Models

• Justify the role of critical care pharmacists on the multiprofessional care team.
• Apply management fundamentals, organizational psychology tenets, and ICU best practices.
• Design strategies to develop and optimize pharmacotherapeutic care for critically ill patients.
• Develop strategies for expanding practice involvement across the spectrum of institutional practice sites. 

Case Series: Critical Care Pharmacist Precepting, Mentoring, and Training

• Compare and contrast use of the four preceptor roles in critical care practice.
• Develop mentorship strategies for lifelong learning and development.
• Design a training program for a critical care pharmacist. 

Resuscitation and Critical Care Practice IV
ACPE #: 0217-9999-24-025-H01-P
Chapter: Medication Safety and Technology in the ICU

• Justify the role of the medication safety officer to improve the care of ICU patients.
• Analyze available quality improvement tools and apply them to improve safe medication use in the ICU.
• Demonstrate how to improve the safe use of medications for patients transitioning out of the ICU.
• Evaluate the technology available to use in the ICU to promote safety and optimize care for critically ill patients.
• Apply simulation-based activities and artificial intelligence to improve the care of ICU patients. 

Case Series: Pharmacy Services in the Telehealth ICU

• Distinguish between traditional bedside critical care services and those provided by telehealth and telecritical care (TCC).
• Evaluate the evidence supporting TCC pharmacist services.
• Design strategies to optimize cost savings in TCC pharmacy.
• Assess existing legal and operational recommendations for telehealth pharmacy practice. 

Resuscitation and Critical Care Practice V
ACPE #: 0217-9999-24-026-H01-P
Case Series: Managing Drug Shortages and Providing Cost-Effective Pharmacotherapy

• Account for the epidemiology of drug shortages affecting the critically ill population.
• Identify how cost-effectiveness is applied to pharmacotherapy decision-making.
• Evaluate the interplay between drug shortages and cost-effective pharmacotherapy in the critically ill population.
• Design a strategy, including both operational and clinical considerations, to optimize the management of drug shortages in the critically ill population.

Faculty Information

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

The following persons in control of this activity’s content have relevant financial relationships:

Consultancies: Brooke Barlow (Grifols); Molly Droege (SaNOtize Research and Development); Gabriel V. Fontaine (AstraZeneca, Chiesi, Marinus Pharmaceuticals, Anticoagulation Forum); Tudy Hodgman (ACCP); Desiree Kosmisky (Carolinas/Virginias Chapter of the Society of Critical Care Medicine); Rachel Kruer (Wolters Kluwer); Brittany Bissell Turpin (Lexicomp); Patrick M. Wieruszewski (La Jolla Pharmaceutical Company)

Grants: Nicole M. Acquisto (Melinta Therapeutics); Tyree (Ty) Heath Kiser (Allergan); Andrea Sikora (AHRQ); Zachary R. Smith (Shields Health Solutions)

Honoraria: Molly Droege (ACCP) (two honoraria) Gabriel V. Fontaine (AstraZeneca, Chiesi, Anticoagulation Forum); Paul M. Reynolds (Prime Medical Education)

All other persons in control of content do not have any relevant financial relationships with an ineligible company. 

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

• Complete the attestation statement
• Review all content
• Complete and pass the assessments
• Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

ACCP and ASHP collaborate on critical care pharmacy activities.